GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XOMA Royalty Corp (STU:X0M1) » Definitions » Cyclically Adjusted PS Ratio

XOMA Royalty (STU:X0M1) Cyclically Adjusted PS Ratio : 7.24 (As of May. 25, 2025)


View and export this data going back to 1986. Start your Free Trial

What is XOMA Royalty Cyclically Adjusted PS Ratio?

As of today (2025-05-25), XOMA Royalty's current share price is €21.20. XOMA Royalty's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was €2.93. XOMA Royalty's Cyclically Adjusted PS Ratio for today is 7.24.

The historical rank and industry rank for XOMA Royalty's Cyclically Adjusted PS Ratio or its related term are showing as below:

STU:X0M1' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.06   Med: 1.77   Max: 10.11
Current: 7.67

During the past years, XOMA Royalty's highest Cyclically Adjusted PS Ratio was 10.11. The lowest was 0.06. And the median was 1.77.

STU:X0M1's Cyclically Adjusted PS Ratio is ranked worse than
61.12% of 499 companies
in the Biotechnology industry
Industry Median: 5.41 vs STU:X0M1: 7.67

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

XOMA Royalty's adjusted revenue per share data for the three months ended in Mar. 2025 was €0.225. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €2.93 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


XOMA Royalty Cyclically Adjusted PS Ratio Historical Data

The historical data trend for XOMA Royalty's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XOMA Royalty Cyclically Adjusted PS Ratio Chart

XOMA Royalty Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.83 3.85 4.21 5.29 8.12

XOMA Royalty Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.88 6.94 8.00 8.12 6.15

Competitive Comparison of XOMA Royalty's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, XOMA Royalty's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


XOMA Royalty's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XOMA Royalty's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where XOMA Royalty's Cyclically Adjusted PS Ratio falls into.


;
;

XOMA Royalty Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

XOMA Royalty's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=21.20/2.93
=7.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

XOMA Royalty's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, XOMA Royalty's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.225/134.9266*134.9266
=0.225

Current CPI (Mar. 2025) = 134.9266.

XOMA Royalty Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 0.385 100.684 0.516
201509 0.312 100.392 0.419
201512 7.441 99.792 10.061
201603 0.595 100.470 0.799
201606 0.065 101.688 0.086
201609 0.094 101.861 0.125
201612 0.082 101.863 0.109
201703 0.035 102.862 0.046
201706 1.268 103.349 1.655
201709 3.669 104.136 4.754
201712 0.499 104.011 0.647
201803 0.045 105.290 0.058
201806 0.231 106.317 0.293
201809 0.092 106.507 0.117
201812 0.176 105.998 0.224
201903 0.772 107.251 0.971
201906 0.098 108.070 0.122
201909 0.852 108.329 1.061
201912 0.043 108.420 0.054
202003 0.075 108.902 0.093
202006 0.036 108.767 0.045
202009 0.043 109.815 0.053
202012 1.574 109.897 1.932
202103 0.028 111.754 0.034
202106 0.066 114.631 0.078
202109 0.071 115.734 0.083
202112 2.131 117.630 2.444
202203 0.249 121.301 0.277
202206 0.081 125.017 0.087
202209 0.040 125.227 0.043
202212 0.123 125.222 0.133
202303 0.036 127.348 0.038
202306 0.133 128.729 0.139
202309 0.068 129.860 0.071
202312 0.146 129.419 0.152
202403 0.118 131.776 0.121
202406 0.303 132.554 0.308
202409 0.056 133.029 0.057
202412 0.188 133.157 0.190
202503 0.225 134.927 0.225

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


XOMA Royalty  (STU:X0M1) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


XOMA Royalty Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of XOMA Royalty's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


XOMA Royalty Business Description

Traded in Other Exchanges
Address
2200 Powell Street, Suite 310, Emeryville, CA, USA, 94608
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.

XOMA Royalty Headlines

No Headlines